Payer and Prior Authorization Barriers
Panelists discuss how payer controls and prior authorization policies delay and derail LDL-lowering therapy.
PCSK9 Inhibitor Underuse
Panelists discuss how PCSK9 inhibitors remain underused due to access, cost, and adherence barriers.
Nonstatin Therapy Decisions
Panelists discuss how nonstatin agents are chosen and when combination therapy should be introduced for high-risk patients.
International LDL Thresholds
Panelists discuss how global LDL thresholds below 55 mg/dL influence care and challenge U.S. practice to evolve.
Reinstating LDL-C Targets
Panelists discuss how reinstating LDL-C targets in quality programs could improve outcomes and accountability.
Unintended Consequences of Metric Changes
Panelists discuss how substituting LDL outcomes with statin-use metrics weakened cholesterol management quality.
The 2013 Guideline Shift
Panelists discuss how removing LDL-C targets in 2013 shifted focus from outcomes to statin use, weakening control efforts.
Social Determinants of Health
Panelists discuss how social determinants such as access, income, and literacy drive disparities in LDL-C control.
Real-World Insights and PROMPT-LIPID
Panelists discuss how real-world programs like PROMPT-LIPID expose undertreatment patterns and guide care improvement.
Pharmacy-Driven Challenges
Panelists discuss how pharmacy-related delays and limited escalation practices widen LDL-C management gaps.
Challenges with Undertreatment in Hyperlipidemia and Opportunities to Address this Gap
Panelists discuss how: clinical inertia, patient apathy, and the asymptomatic nature of high cholesterol all contribute to undertreatment and poor outcomes.
Understanding the Current State of LDL-C Goal Attainment and Barriers to Adequate Control in Hyperlipidemia
Panelists discuss how: LDL-C control remains a national crisis, with many patients not on therapy or failing to reach target levels despite the availability of effective treatments.
